Navigation Links
Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
Date:12/7/2010

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC).

After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12 g/dL, while no patients receiving placebo experienced this increase. In addition, patients who received ALD518 had an average lean body mass loss of 0.19 kg, compared to an average loss of 1.5 kg in those who received placebo. Additional symptoms of the disease such as fatigue were also reduced in patients who received ALD518.

The data was presented by Michael Schuster, M.D., director of the hematologic malignancy program at Stony Brook University Medical Center, at the annual meeting of the American Society of Hematology. The presentation, titled "Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial," took place on Monday, December 6.

"The anemia of chronic disease that is seen in cancer patients is in large part due to IL-6 stimulation of hepcidin, resulting in reduced plasma iron levels," said Dr. Schuster. "Given the recent safety concerns over the use of ESAs, alternative therapeutic approaches that target IL-6, such as ALD518, would be very desirable and could potentially reduce the requirement for transfusions in this patient population."

Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals, added, "We continue to be encouraged by strong clinical data from ALD518 in the areas of cancer, cancer supportive care and cancer anemia. We look forward to continuing our clinical investig
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., ... is pleased to announce that its animal research ... for the Assessment and Accreditation of Laboratory Animal ... of animals in science worldwide through voluntary accreditation ... for animal care and use in 38 countries. ...
(Date:7/14/2014)... , July 14, 2014  Today, ATS Labs, ... that it acquired the assets of MicroTest Labs, Inc. ... acquisition of MTL is the first step in the ... laboratory services platform to support the medical device and ... as Accuratus Lab Services , a name that ...
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8
(Date:7/14/2014)... Last month Bromell Agency officially launched the ... features more detailed information on how clients can protect ... and boats in the state of Louisiana. , The ... the website in order to better educate clients on ... of the website, which is to display comprehensive insurance ...
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... 2014 Physical fitness may buffer some of the adverse ... new study by researchers from the American Cancer Society, ... study appears in the journal Mayo Clinic Proceeding ... and obesity and blood markers associated with cardiovascular disease ... , Sedentary behavior has been linked to an increase ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
(Date:7/14/2014)... -- Being physically active in middle age appears to ... types of dementia, suggest the findings from two new ... exercise at various levels, especially in midlife, is beneficial ... Clinic, said in an Alzheimer,s Association news release. ... conclusive. More research is needed to determine the extent ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Staying Active May Help Prevent Dementia 2
... Food and Drug Administration,s (FDA) recent decision to approve ... treatment of non-Hodgkin,s lymphoma (NHL). "This is ... M. Graham, M.D., Ph.D., president of SNM and director ... College of Medicine. "We,ve known for some time that ...
... , ... superstore has beaten the thirty cents per card - three day production threshold on quantities ... Fort ... so few plastic cards so fast and at this price level. This is a special ...
... , , Members Take to ... with Constituent Health Care Stories to Congress , ... health care reform speech, and with Congress back to work in Washington, AARP ... what,s broken and preserve what,s right. , , ...
... , BELGRADE, Serbia, Sept. 10 /PRNewswire-FirstCall/ - HTDS ... its operating subsidiary Slavica Bio Chem www.slavicabiochem.com ... , , The equipment is ... http://www.expressionproteomics.com/LifeScience/pdf/Bulletin_3095.pdf , , , Dr.Ivana Gadjanski HTDS ...
... TEANECK, N.J., Sept. 10 After an 8 day trial, ... on September 4, 2009 by the Superior Court of New Jersey ... breaching her duty of loyalty. , , ... 2009, Ellen Koblitz, Presiding Judge of the Superior Court of New ...
... WALTHAM, Mass., Sept. 10 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... several healthcare industry investor conferences during the month of September. , ... Chief Executive Officer, and Jon Russell, Vice President, Finance, will attend ...
Cached Medicine News:Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:My1Stop.com Offers Plastic Card Printing Promotion Beats the Thirty Cents per Card Threshold - Offering 1000 Cards in Only Three Days for $299 2Health News:AARP Delivers Health Care Reform 'Message in a Bottle' in Chicago 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 2Health News:Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects 3Health News:Inverness Medical Innovations Announces September Investor Conference Schedule 2
... The VersaPulse® PowerSuite™ holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: